Werfen Life Divests to Focus on the Hemostasis Market

Werfen Life Divests to Focus on the Hemostasis Market

The growing prevalence of autoimmune and blood disorders has put a spotlight on the science of hemostasis, the process of stopping bleeding and keeping blood within the damaged blood vessel. The coagulation/hemostasis analyzer market is expected to reach $4.84 billion by 2021, according to a report from MarketsandMarkets. Among the products, clinical laboratory analyzers are expected to account for the largest share of the market. Some big name players are already strengthening their hemostasis portfolios. In December 2015, Mallinckrodt plc (NYSE: MNK) purchased a global portfolio of three hemostasis products from The Medicines Company (NASDAQ: MDCO) for an upfront payment of $175... Read More »

Behavioral Health Company Goes Public after Acquisition

The Behavioral Health sector isn’t charging into the New Year. Only two deals have been announced in the first three weeks of January, but one of those is unusual for the sector. On January 11, 2017, Global Partner Acquisition Corp. (NASDAQ: GPAC), a blank-check company formed for the purpose of effecting a business combination, merged with Alabama-based Sequel Youth and Family Services, a portfolio company of Levine Leichtman Capital Partners. Sequel Youth and Family Services now operates 44 residential and community-based programs in 19 states that offer diversified behavioral health services for children, adolescents and adults with behavioral, emotional or physical challenges. In March... Read More »

Urgent Care Centers May Benefit from ACA Repeal

Last week, the Urgent Care Association of America (UCAOA) released its annual Benchmarking Report. In it was the finding that the number of urgent care centers increased 10% in 2016, to 7,357 centers. Looking through our database, it’s obvious that the majority of that year-over-year growth in urgent care centers was de novo, not from mergers and acquisitions. Here’s how M&A in the urgent care segment has played out since 2010, the year the Affordable Care Act was signed. Urgent Care Center Deals, 2010 to 2016 YearNumber of DealsTotal $ Spent 201612N/A 201517$1.06 billion 20149$2.2 million 20132N/A 201210$7.8 million 20114N/A 20102$805 million #rowspan#Source: HealthCareMandA.com Only... Read More »

Pharmaceutical Deals Celebrate the New Year

The Pharmaceutical sector hasn’t wasted any time getting busy in the New Year. As of January 18, 2017, 10 pharma deals have been announced, with disclosed prices totaling $7.18 billion. Of course, the annual JP Morgan Healthcare Summit, held this year from January 9 to January 13, helped to boost the announcements. The largest deal so far was Takeda Pharmaceutical Co. Ltd.’s (OTCQB: TKPYY) $4.67 billion ($24.00 per share) takeover of ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA). ARIAD is an oncology company that discovers, develops and commercializes drugs for patients with rare cancers. A large motivator for the deal was to gain access to Iclusig® (ponatinib), a globally commercialized... Read More »